Business · regulatory

Mile High Labs Files Type II DMF #044151 With FDA for CBD Isolate

The Loveland, Colo., ingredient maker opened a confidential FDA regulatory file on its CBD isolate, a supply-chain credential aimed at pharmaceutical buyers.

By Mei Chen, Cannabis Tech ReporterPublished November 19, 2026Updated November 19, 20264 min read
Minimalist photo of white pills and an open bottle on a white background, emphasizing emptiness.

Minimalist photo of white pills and an open bottle on a white background, emphasizing emptiness.

Mile High Labs filed a Type II Drug Master File (DMF #044151) with the FDA for its CBD isolate, giving drug developers a way to cite its manufacturing data and signaling a push beyond wellness into pharmaceutical supply.

What Mile High Labs filed with the FDA

Mile High Labs filed a Type II Drug Master File, assigned DMF #044151, covering its CBD isolate.

The company, based in Loveland, Colo., describes itself as a developer of hemp-derived cannabinoid ingredients. A company press release carried by MGRetailer on Nov. 19, 2026, disclosed the filing.

The release excerpt available to CannIntel confirms the filer, the DMF number and the product. It doesn't list the full scope of the dossier or any FDA acknowledgment. Those details matter, and they're not public yet.

How a Type II DMF works, and what it doesn't do

A DMF is a confidential submission that lets one company's data support another company's drug application, and it is not an FDA approval.

Type II DMFs cover drug substances, drug substance intermediates and the materials used to make them. A supplier files once. Its customers, typically drug sponsors, then cite the file in their own INDs, NDAs or ANDAs through a letter of authorization.

The FDA doesn't review a DMF on its own. It looks at the file only when a sponsor's application references it. A DMF number, then, is a credential. Not a clearance.

Three things the filing does not do:

  • It does not make the CBD isolate an FDA-approved drug ingredient.
  • It does not change the legal status of CBD in dietary supplements or foods.
  • It does not guarantee any customer will reference the file.

Why pharma-grade positioning matters for isolate suppliers

CBD isolate is a commodity, and a DMF is one way to separate a quality-controlled supplier from the pack.

Isolate pricing has been under pressure for years as hemp acreage and extraction capacity outran demand. Suppliers chasing margin have two options: scale on cost or move up the quality ladder. A regulatory file is a ladder rung.

Epidiolex remains the only FDA-approved CBD drug, a plant-derived oral solution from Jazz Pharmaceuticals (which acquired GW Pharmaceuticals). Any company developing a competing or novel CBD-based drug needs a documented, auditable source of drug substance. That's the buyer Mile High Labs is courting.

It's a smart play. It's also a long one.

The supply-chain angle operators should watch

A DMF puts a documented quality system behind the ingredient, which is the same story brands selling into regulated channels increasingly need to tell.

For consumer brands buying isolate, the filing is a signal about upstream controls, not a label claim they can borrow. They should not market a product as DMF-backed or FDA-reviewed, because doing so invites the kind of warning-letter attention the agency has aimed at CBD marketers for years.

Procurement teams can still ask pointed questions. Is the supplier willing to share a letter of authorization context, a certificate of analysis tied to batch records, and audit rights? A supplier with an open DMF has presumably built the paperwork habits to answer.

Vendor-selection checklist for isolate buyers:

  1. Request batch-level COAs for cannabinoid potency, residual solvents, heavy metals and pesticides.
  2. Ask whether the supplier operates under cGMP and which standard it audits to.
  3. Confirm how the supplier documents change control, since DMF holders must notify referencing customers of changes.
  4. Get any regulatory claims in writing before repeating them in marketing.

The regulatory backdrop: still no FDA CBD pathway for supplements

The FDA has not created a lawful route for CBD in conventional foods or dietary supplements, so drug-substance credentials remain the clearest regulated lane.

For years the agency has maintained that CBD can't be marketed in food or supplements because it was first studied as a drug. It has said existing frameworks aren't suited to CBD and has pointed toward Congress for a new pathway. That stalemate hasn't broken.

In that environment, a drug-oriented filing is less a bet on the supplement market than a hedge against it. If a legislative fix arrives, a documented supplier is positioned. If it doesn't, the pharmaceutical lane stays open.

For full background on how the agency has handled CBD, see the CannIntel topic hub on FDA CBD regulation. The 2018 Farm Bill's hemp provisions and the agency's long-running supplement position still frame everything here.

The next signal to watch: whether Mile High Labs names a pharmaceutical customer or a referencing application. Until a sponsor cites DMF #044151, the filing is infrastructure waiting for a buyer.

Sources

Mile High LabsDrug Master FileCBD isolateFDAhemp-derived cannabinoidspharmaceutical supply chain
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.

Related from Business

More from the newsroom